Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions News feed Embed this list Save this search Mark all Export Your filters: cql: author="CATALANO, J" or (type exact bookEditor and editor="CATALANO, J") Mark conference C3 FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation H Ghesquieres, J Seymour, Fritz Offner (UGent) , P Feugier, P Brice, C Haioun, O Casasnovas, J Catalano, F Jardin, L Xerri, et al. (2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-188 Mark conference C3 Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study G Salles, J Catalano, P Feugier, Fritz Offner (UGent) , R Bouabdallah, D Caballero, P Brice, LM Pedersen, C Haioun, D Belada, et al. (2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(suppl. 2). p.229-229 Mark journalArticle A1 CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 105(4). p.1417-1423 Mark conference C3 Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up P SOLAL-CELIGNY, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 106(11). Mark conference C3 An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2003) BLOOD. 102(11).